Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study not identified

Story checked

Existing cancer drug reduces blood vessel malformations in the brain (opens in a new tab)

medicalxpress.com · 2026-10-21

Short answerEvidenceSource

Short answer

Source study not identified

Study not confirmed.

The search did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.

32 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

No source study could be identified.

The available search results did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.

View article claims
3

Search result

No source study found.

The available search results did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.

Source paper

Source layer

The paper behind the story

The source record for this check.

The research anchor for the report.

  • Also referencedpresented as the new finding

    The kinase inhibitor dabrafenib halts progression of cerebral cavernous malformations in a BRAF-independent manner

    Publisher (opens in a new tab)
The literature search

32 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 28 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 6Not checkedResearchers identified a substance that reduces blood vessel lesions in the brain in cerebral cavernous malformation (CCM).View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 6Not checkedThe substance is already used to treat brain tumors in children and could therefore be repurposed relatively rapidly to treat CCM, potentially replacing surgery.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 6Not checkedIn the study, published in Science Translational Medicine, more than 5,000 bioactive molecules were screened on cultured CCM mouse vascular cells, and top candidates were then studied in cultured human brain vascular cells and CCM animal models.View evidenceHide evidence

As statedmore than 5,000 bioactive molecules

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 6Not checkedDabrafenib, a BRAF inhibitor, efficiently reversed the pathological phenotype in vitro and halted cavernoma progression in vivo.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 6Not checkedIn a mouse model with CCM, dabrafenib reduced the number and size of lesions, stabilized vessels, suppressed lesion leakage, and could also correct structural defects in the retinal vasculature.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 6 of 6Not checkedThe authors argue that dabrafenib's existing FDA and EMA approval and safety profile make it a strong candidate for rapid clinical translation to halt brain cavernoma growth and progression.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

Crossref, Europe PMC, PubMed · 31 candidate papers

Candidate

Translational Journal of the American College of Sports Medicine: 2025 Paper of the Year

Translational Journal of the American College of Sports Medicine · 2026 · Crossref

Source (opens in a new tab)

Explore all search results